Calcitonin

Calcitonin Salmon (Miacalcin / Fortical) — Antiresorptive Peptide Hormone

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

A 32-amino-acid peptide hormone that reduces osteoclast activity and lowers serum calcium. Calcitonin salmon remains FDA-approved for selected bone and calcium disorders, but its role in osteoporosis is now limited and current labeling states that fracture-reduction efficacy has not been demonstrated.

Plain English

Calcitonin slows the activity of cells that break down bone and can quickly lower elevated blood calcium. It was once used much more widely for osteoporosis, but newer treatments generally provide stronger fracture protection. Calcitonin still has established clinical uses, particularly in certain cases of Paget’s disease and hypercalcemia, while long-term osteoporosis use is now more limited.

Overview

Calcitonin is a 32-amino-acid peptide hormone involved in calcium and bone metabolism. Pharmaceutical calcitonin salmon activates calcitonin receptors on osteoclasts, reducing bone resorption and lowering serum calcium. FDA-approved calcitonin salmon products have formulation-specific uses, including selected treatment of postmenopausal osteoporosis, symptomatic Paget’s disease, and hypercalcemia. Its role in osteoporosis has declined substantially because more effective alternatives are available and because long-term calcitonin use has been associated with a possible increased malignancy risk.

Research Summary

Calcitonin salmon has decades of human clinical experience. The 5-year PROOF trial reported a reduction in new vertebral fractures with the 200 IU/day nasal dose, but other tested doses did not show the same statistically significant effect and current U.S. labeling states that fracture-reduction efficacy has not been demonstrated. Injectable calcitonin remains useful for selected patients with symptomatic Paget’s disease and for early treatment of hypercalcemic emergencies because it can lower serum calcium relatively quickly. A meta-analysis of randomized trials found a higher incidence of malignancies among calcitonin-treated patients than placebo-treated patients, although a definitive causal relationship has not been established. European regulators subsequently removed nasal calcitonin’s osteoporosis use.

Research Areas

  • Osteoporosis
  • Paget's disease
  • Hypercalcemia
  • Acute vertebral fracture pain
  • Osteoclast biology
  • Bone resorption

Safety & Risks

Serious Risks

  • Serious hypersensitivity reactions, including anaphylaxis, have been reported with calcitonin salmon
  • Hypocalcemia can occur and should be corrected before treatment
  • A meta-analysis of randomized trials found a higher incidence of malignancies in calcitonin salmon-treated patients than placebo-treated patients; a definitive causal relationship has not been established
  • Because of the possible malignancy association, the need for continued calcitonin therapy should be periodically re-evaluated

Reported Side Effects

  • Nasal irritation, rhinitis, or epistaxis with intranasal formulations
  • Nausea and vomiting, especially with injectable formulations
  • Facial flushing
  • Injection site reactions
  • Headache
  • Hypocalcemia
United States
FDA-approved calcitonin salmon products have formulation-specific indications. Nasal calcitonin salmon is approved for postmenopausal osteoporosis in women more than 5 years after menopause when alternative treatments are not suitable; current labeling states that fracture-reduction efficacy has not been demonstrated. Injectable calcitonin salmon is approved for selected uses including symptomatic Paget’s disease, hypercalcemic emergencies, and postmenopausal osteoporosis when alternatives are not suitable.
United Kingdom
Prescription only; MHRA-approved but use has declined due to cancer signal
Australia
TGA Schedule 4; available but rarely first-line
Canada
Health Canada-approved; prescription only

Citations & Sources